National
Reid recommits to ‘Don’t Ask’ repeal in lame duck
Senators talk of extending session to vote on gay ban
Senate Majority Leader Harry Reid reaffirmed on Monday his commitment to bring a vote "Don't Ask, Don't Tell" repeal (Blade photo by Michael Key).
Senate Majority Leader Harry Reid (D-Nev.) reaffirmed on Monday his commitment to bring “Don’t Ask, Don’t Tell” repeal to vote in the lame duck session of Congress amid fears other legislative priorities will bump the issue from the agenda.
Reid pledged to repeal “Don’t Ask, Don’t Tell” by year’s end on the Senate floor as he described a litany of legislative items he wants the chamber to take on during lame duck, including passage of the DREAM Act, renewing tax cuts for middle class families and ratification of the START Treaty.
“We’re also going to repeal the discriminatory ‘Don’t Ask, Don’t Tell’ law,” Reid said. “We’re going to match our policy with our principles and finally say in the United States, everyone who steps up to serve our country can be welcome.”
Legislation to repeal the military gay’s ban is pending before the Senate as part of the fiscal year 2011 defense authorization bill. A previous attempt to bring the legislation to the Senate floor in September failed when a united Republican caucus blocked consideration of the measure.
Many senators — including Sens. Susan Collins (R-Maine), Olympia Snowe (R-Maine) and Blanche Lincoln (D-Ark.) — said they wanted a more fair amendment process with more amendments for the minority as a condition to moving forward with the legislation.
In his remarks, Reid said Republicans are blocking consideration of the defense authorization bill because they don’t believe they have the votes to take out the “Don’t Ask, Don’t Tell” provision by amendment once the legislation reaches the floor.
Reid said when Republicans refuse to debate the defense authorization bill, they also “hold up a well-deserved raise for our troops, better health care for our troops and their families” as well as other important initiatives for the U.S. military.
A White House official, who spoke on condition of anonymity, also affirmed President Obama wants Congress to repeal “Don’t Ask, Don’t Tell” before lawmakers adjourn for the year.
“The White House remains fully committed to passage of the National Defense Authorization Act, including the repeal of ‘Don’t Ask, Don’t Tell,’ during the lame duck,” the official said. “This is a priority for the president, and are we confident that the Congress will be able to address this issue this year.”
Concern that “Don’t Ask, Don’t Tell” repeal may have fallen from the schedule emerged when Reid offered remarks earlier in the day and didn’t include the defense authorization bill as among the legislative items for which he would file cloture on Monday.
Instead he listed other items, including the DREAM Act and legislation that would provide healthcare benefits and compensation to workers who responded to Ground Zero during the Sept. 11, 2001 terrorist attacks.
Reid only mentioned the defense authorization bill after Senate Armed Services Committee Chair Carl Levin (D-Mich.) reminded him on the floor to say something about the legislation.
The majority leader responded by saying he had bipartisan conversations on Sunday about trying to find a way to move forward with the defense authorization bill.
“The issue on that, Madam President, is what we do with amendments,” Reid said. “And without belaboring the point here, I would be happy to consider doing a number of amendments if we had time agreements on those amendments. But to just have an open process — at this stage, I don’t see how we can do that.”
Jim Manley, a Reid spokesperson, said Reid didn’t include “Don’t Ask, Don’t Tell” among the items on which he would file cloture on Monday because the Senate leadership is still in talks to find enough Republican support to move forward with the defense authorization bill.
“Discussion are ongoing that involve Sen. Levin, Sen. [Joseph] Lieberman, Sen. Collins and others about trying to put together a debate that will satisfy folks and both of the aisle,” Manley said.
Manley said he couldn’t make a prediction on when these discussion would conclude, but said Reid remains committed to bringing up the legislation to a vote during lame duck.
Despite the commitment from Reid for a vote on “Don’t Ask, Don’t Tell,” concerns that time will run out before lawmakers act persist.
In a brief exchange with the Washington Blade on Capitol Hill, Senate Armed Services Committee Chair Carl Levin (D-Mich.) expressed concerns about being able to move forward with the defense authorization in the limited time that remains in the session.
“The longer this go on the more difficult it becomes, but I’m obviously … still hopeful,” Levin said.
Christopher Neff, deputy executive director of the Palm Center, a think tank on gays in the military at the University of California, Santa Barbara, acknowleged that time is an issue as he said he still sees a path forward for repeal.
“The calendar, in my estimation, has always been a bit more difficult than the vote count, but I do think that there are scenarios where this can be finalized for a signature before Congress adjourns,” Neff said.
Neff cited what he perceived as Obama’s commitment to repeal as a reason for why repeal can still happen and noted a recent call the president made to Levin against stripping the defense authorization bill of its “Don’t Ask, Don’t Tell” language.
“President Obama has shown strong leadership in reaching out to Sen. Levin and to Sen. Reid to try to move this process forward,” Neff said. “I think the White House has taken a leadership role on this and they want to see it delivered and I think there’s more to be done.”
Talk is emerging about extending the legislative session beyond what was previously planned to accomodate a vote on “Don’t Ask, Don’t Tell” repeal.
During his earlier remarks, Reid set Dec. 17 as the target date for when he wants the Senate to adjourn for this Congress and said he doesn’t think his colleagues want to stay until Christmas Eve as they did last year.
But Manley said the Dec. 17 target date for adjournment is “not hard and fast” and “we’ll have to wait and see how long we’re going to need.” He added the entire Democratic caucus would agree to extending the session for that to happen.
In a statement, Sen. Mark Udall (D-Colo.) said the Senate should stay in session for until the remainder of the calendar year if that’s what’s necessary to complete legislative work before the chamber, such as passage of the defense authorization bill.
“It’s time to follow Elvis Presley’s advice — we need ‘a little less conversation, and a little more action,’” Udall said. “I’m willing to stay through Christmas and New Year’s, if that’s what it takes, to fight for middle-class tax relief, the defense authorization bill, public lands legislation — which means jobs for Coloradans — and other important work.”
On Monday, the Huffington Post reported that Lieberman and Sen. Kirsten Gillibrand (D-N.Y.) were in favor of extneding the legislative session to pass “Don’t Ask, Don’t Tell” repeal.
“Sen. Lieberman believes that there are at least 60 votes to repeal ‘Don’t Ask, Don’t Tell’ this year, provided that leadership allows time for sufficient debate and amendments,” Lieberman spokeswoman Erika Masonhall was quoted as saying. “Wanting to go home is not an acceptable excuse for failing to pass a bill that provides essential support for our troops and veterans and failing to take action that the president, the Secretary of Defense and the chairman of the Joint Chiefs of Staff have called for.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
‘Dogs of Venice’ looks at love lost and rediscovered
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Lighting candles in a time of exhaustion
Why queer spaces often fail South Asian women
